# Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

> **NCT06911684** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 88 (estimated)

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **COMBINATION_PRODUCT:** lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
- **COMBINATION_PRODUCT:** lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy

## Key facts

- **NCT ID:** NCT06911684
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2031-12-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911684, "Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06911684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*